Neuroya

Company Overview

Snapshot

Founded in February 2017 by Moshe Daninos, Neuroya operates with 1–10 employees. The company has raised $50,000 across one funding round. Neuroya ceased operations in December 2020.

Business overview

Neuroya develops a brain-computer interface designed to optimize the diagnosis and management of common neuropathologies such as attention deficit hyperactivity disorder, stroke, and autism. The company's platform translates observations and understanding of the nervous system to manipulate behavior-related neural processes, aiming to restore or enhance functions. Utilizing continuous data collection and algorithms, Neuroya suggests personalized treatments and provides real-time representation of brain activity through smart devices, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices.

Company Intelligence Q&A

What is Neuroya's primary focus?

Neuroya focuses on developing a brain-computer interface to optimize the diagnosis and management of common neuropathologies, including attention deficit hyperactivity disorder, stroke, and autism.

When was Neuroya founded?

Neuroya was founded in February 2017.

What is the status of Neuroya?

Neuroya is non-active and ceased to operate in December 2020.

Who is a key founder of Neuroya?

Moshe Daninos is a founder and CSO of Neuroya.

What technology does Neuroya utilize?

Neuroya utilizes artificial intelligence and algorithms to provide personalized treatments and real-time brain activity representation through smart devices.